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Background: Left atrial ﬂutter following atrial ﬁbrillation (AF) ablation is increasingly common and
difﬁcult to treat. We evaluated the safety and efﬁcacy of ablation of the anteroseptal line connecting the
right superior pulmonary vein (RSPV) to the anteroseptal mitral annulus (MA) for the treatment of
perimitral ﬂutter (PMF).
Methods: We systematically studied patients who were previously treated with AF ablation and who
presented to the electrophysiology laboratory with atrial tachyarrhythmias between January 2000 and
July 2010. The diagnosis of PMF was conﬁrmed by activation mapping and/or entrainment. After re-
isolation of any recovered pulmonary vein, a linear radiofrequency (RF) ablation was performed on the
line that connected the RSPV to the anteroseptal MA. In this analysis, we included only patients who
were treated with an anteroseptal line for their PMF.
Results: Ablation was performed at the anteroseptal line in 27 PMF patients (63713 years; 9 women)
who had undergone prior ablation for paroxysmal (n¼3) or persistent (n¼24) AF, using electroanatomic
activation mapping (70% CARTO, 30% NavX). The anteroseptal ablation line was effective in 22/27 (81.5%)
patients in the acute-care setting. Termination of AF to sinus rhythm occurred in 15/22 (68.2%) patients,
and 7/22 (31.8%) patients' AF converted to another right or left atrial ﬂutter. At the 6-month follow-up,
20% of patients demonstrated recurrent left atrial tachyarrhythmia. Only one patient required repeat
ablation, and the remaining patients' condition was controlled with antiarrhythmic medications. No
major procedural complications or heart block occurred.
Conclusion: Ablation at the left atrial anteroseptal line is safe and efﬁcacious for the treatment of PMF.
Unlike ablation at the traditional mitral isthmus line, ablation at the left atrial anteroseptal line does not
require ablation in the coronary sinus.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Atrial ﬁbrillation (AF) is the most common sustained arrhythmia,
and as the average age of the population increases, the incidence of
AF will continue to rise [1,2]. The past decade has seen the steady
advance of catheter-based approaches to the management of AF.
Fortunately, serious complications arising from AF ablation have
declined as collective experience has increased and techniques have
improved. Pulmonary vein stenosis, atrial-esophageal ﬁstula, cere-
bral vascular accidents, and coronary artery injury are now uncom-
mon complications [3]. Despite these advances, the prevalence of
late-onset postprocedural left atrial (LA) ﬂutter remains as high as
10% [4]. Presumably, in LA ﬂutter, the conversion of AF to a more
organized reentrant circuit results in the development of macro-
reentrant atrial tachycardias. These tachycardias possibly result
from “proarrhythmic” lesion sets that create areas of slow conduc-
tion, predisposing the circuit to reentry [5].
Perimitral ﬂutter (PMF) is responsible for a considerable
percentage of cases of macroreentrant LA ﬂutter, especially in
the setting of AF ablation [6]. Despite recent technological
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advances and a better understanding of the anatomy, mitral
isthmus ablation remains technically challenging, often requiring
substantial ablation (415 min of radiofrequency [RF] energy),
high ablation powers (r50 W), and epicardial ablation within
the coronary sinus (CS) in approximately 70% of patients. Even so,
success rates for mitral isthmus ablation in the acute setting are
only moderately high [7].
The present study sought to evaluate the feasibility, safety, and
efﬁcacy of ablation at the LA anteroseptal line connecting the right
superior pulmonary vein (RSPV) to the anteroseptal mitral annulus
(MA) for the treatment of PMF.
2. Material and methods
2.1. Study population and follow-up
We retrospectively analyzed patients who were treated for PMF
with catheter ablation for atrial tachyarrhythmias, at the ante-
roseptal line connecting the RSPV to the anteroseptal MA. The
study was approved by the Institutional Review Board of the
Cleveland Clinic Foundation.
From June 2000 to July 2010, ablation at the anteroseptal line was
performed in 27 patients with PMF that was either the presenting
arrhythmia or an organized intermediate rhythm during AF ablation.
All patients provided written informed consent. The baseline char-
acteristics of the study population are presented in Table 1.
During the ﬁrst 3 months after ablation, patients used an event
recorder to monitor for arrhythmias and recorded them on a weekly
basis and whenever they were symptomatic. Additional event recor-
der monitoring was obtained beyond the 3-month period if patients
either had atrial tachyarrhythmia within the ﬁrst 3 months or had
symptoms consistent with arrhythmia. Patients underwent 24-h
Holter ECG at 3 months, 6 months, and every 6 months thereafter.
Follow-up visits were scheduled at 3, 6, and 12 months after ablation
and yearly thereafter when possible. More frequent follow-up was
scheduled for patients who had symptoms, arrhythmia recurrence, or
complications from the procedure. All patients underwent transthor-
acic echocardiography within 3 months before ablation, echocardio-
graphy, and cardiac computed tomography to assesses for possible
pulmonary vein (PV) stenosis at 3 months after ablation.
Arrhythmia recurrence was identiﬁed when patients reported
symptoms consistent with arrhythmia and/or when an atrial tachyar-
rhythmia lasting 30 s was captured on a 12-lead ECG, event record-
ing, or Holter monitor recording. Without such documentation,
patients were considered arrhythmia-free. Antiarrhythmic drugs
(AADs) were used during the ﬁrst 2 months after ablation and were
then stopped unless continued arrhythmia indicated their use, in
which case patients were considered to have arrhythmia recurrence.
2.2. Ablation strategy
We have previously described our pulmonary vein isolation (PVI)
and periprocedural anticoagulation protocols in detail [8,9]. Brieﬂy,
all AADs were stopped 4–5 half-lives before ablation, with the
exception of amiodarone, which was discontinued Z4–5 months
before the procedure. A transesophageal echocardiogram was
obtained for patients presenting with AF if they had a subtherapeutic
international normalized ratio r3 weeks before ablation. A 10-Fr
phased-array intravascular ultrasound catheter (Siemens AG Inc.,
Malvern, PA, USA) was placed in the right atrium to assist with
performing transseptal punctures, to guide catheter location and
manipulationwithin the LA, and to monitor for cardiac complications
during ablation. In all patients, all PV antra were re-isolated under
intracardiac echocardiographic (ICE) guidance.
After completion of the re-isolation of the PV antra, the PMF was
mapped using the NavX or CARTO 3-dimensional (3D) electroana-
tomic system and then conﬁrmed by entrainment from the proximal,
distal coronary sinus and the anterior mitral annulus.
2.3. Ablation at the anteroseptal line and veriﬁcation of block across
the line
The anteroseptal line was created between the anterior/antero-
medial aspect of the mitral annulus and the ostium of the RSPV
(Fig. 1). The ablation catheter was advanced through the transseptal
sheath to the anterior/anteromedial mitral annulus, and delivery of
Table 1
Baseline characteristics of the perimitral ﬂutter
study population (n¼27).
Patient characteristics
Age (years) 63713
Women 33.33%
Ejection fraction 52% (23%–65%)
Structural heart disease
No heart disease 11/27
Ischemic heart disease 2/27
Valvular heart disease 4/27
Medications
Beta blockers 11/27
Calcium-channel blockers 8/27
Digoxin 3/27
Amiodarone 1/27
Dofetilide 3/27
Sotalol 3/27
Class IC antiarrhythmics 8/27
Right Antrum
Left Antrum
Anterior MV
Posterior MV
Posterior Wall
Fig. 1. Schematic representation of the anteroseptal line joining the right superior
antrum with the anteroseptal mitral annulus.
Ablation lesions 
Mitral annulus 
Fig. 2. Electroanatomic map of the right and the left atrial chambers of a patient
with perimitral ﬂutter with RF ablation line from the RSPV to the anteroseptal MA.
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radiofrequency lesions was started when the atrioventricular voltage
ratio was 1:2. The ablation was performed using 3D electroanatomic
mapping guidance by rotating the catheter counterclockwise until it
reached the scar of the RSPV (Fig. 2). The transseptal sheath is
typically positioned at the level of the interatrial septum, so during
ablation of the roof of the RSPV, extra caution was taken by applying
gentle pressure to the ablation catheter.
While pulling back, RF energy was applied at each point for 30–
60 s until a signiﬁcant reduction or elimination of the local potential
was reached. To achieve the desired power delivery, irrigated RF
energy was delivered at a power of 30–35W using irrigation rates of
30 mL/min. Temperature was limited to 40 1C.
A complete block was achieved along the ablation line and
documented after restoring sinus rhythm. Sinus rhythmwas restored
using one of the following methods: (1) evaluation of the coronary
sinus activation pattern during pacing just laterally and medially to
the line with the ablation catheter (the translinear pacing maneu-
ver); with this method, a complete linear block was conﬁrmed if
pacing laterally to the line resulted in a distal-to-proximal CS
activation pattern and if after pulling back the catheter to the septal
side of the line, CS was activated from proximal to distal; or
(2) differential pacing maneuvers (Fig. 3).
3. Results
Ablation at the anteroseptal line was performed in 27 PMF
patients (aged 63713 years; 9 female) with prior ablation for
paroxysmal (n¼3) or persistent (n¼24) AF using electroanatomic
activation mapping (70% CARTO, 30% NavX). All patients had
previously been treated with Z1 AF ablation procedure. After
re-isolation of any recovered PV, a linear RF ablation was per-
formed connecting the RSPV to the anteroseptal MA.
3.1. Acute procedural success
The line was acutely effective in 22/27 (81.5%) patients. AF
termination to sinus rhythm occurred in 15/22 (68.2%) patients,
and 7/22 (31.8%) patients' arrhythmia converted to another right
or left atrial ﬂutter. These secondary ﬂutters were mapped and
ablated as well. All patients left the electrophysiology lab with
restored sinus rhythm.
3.2. Follow-up
At 6-month follow-up, 20% of patients demonstrated recurrent
LA tachyarrhythmia. Only one patient required repeat ablation,
and the remaining patients' arrhythmias were controlled with
AADs. The patient who required repeat ablation had recovery of
the conduction across the successfully ablated line and had no
documented arrhythmia recurrence at follow-up visits.
Fig. 3. This a left anterior oblique view of the left atriumwith the circular mapping catheter placed over the septum of the left atrium. Pacing with the ablation catheter from
the superior MA position (12 o'clock) to inferior to the line (circular mapping) 280 ms compared to pacing from anterolateral MA (2 o'clock) to circular mapping inferior to
the line is 237 ms (note in the both images CS activation is distal to proximal).
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3.3. Complications and safety issues
No major procedural complications or heart block occurred. No
patients experienced steam pop, cardiac tamponade, or throm-
boembolic events.
4. Discussion
This retrospective analysis provided information on the feasi-
bility, efﬁcacy, and safety of performing ablation at the antero-
septal line for the treatment of PMF. It described a technique for
terminating PMF, which was achieved in 81.5% of patients and
resulted in 96% of patients being free of arrhythmia.
Ablation at the classical mitral isthmus line, extending from the
left inferior PV to the lateral mitral annulus, is far from the ideal
approach to ablation in PMF. Several studies have made it clear that
the anatomy of the mitral isthmus is not uniform and exhibits
signiﬁcant variation. In their series of 100 consecutive patients, Jais
et al. required 430 min of RF delivery in 20% of patients to achieve
complete block [6]. In postmortem studies, the distance between
the left inferior PV and the lateral mitral annulus averaged 35 mm
length and approximately 4 mm depth: longer than the cavotricus-
pid isthmus with similar myocardial thickness. Certain anatomic
features have been suggested as possible obstacles to successful
mitral isthmus ablation [10–13]: myocardial depth 45 mm; con-
vective cooling by local blood vessels, such as the CS and circumﬂex
artery, that act as a heat sink; a myocardial sleeve around the CS
and continuities with the atrial myocardium that may bridge the
lesion line; crevices in the isthmus area that may hinder safe and
efﬁcient RF energy delivery; continuation of atrial myocardium onto
the atrial aspect of the mitral valve leaﬂet; and epicardial connec-
tions (e.g., the ligament of Marshall) across the mitral isthmus line.
Several cases of injury to the circumﬂex artery owing to ablation
of the lateral mitral isthmus and inside the CS have been reported.
The circumﬂex artery and the CS share a close relationship. Takahashi
et al. reported the ﬁrst case of acute circumﬂex artery occlusion
during CS ablation, which was performed to achieve mitral isthmus
block [14]. Hasdemir et al. found that the circumﬂex artery was
o2 mm from the CS catheter at the lateral and anterolateral mitral
annulus in 24% of patients [15]. Wittkampf et al. postulated that the
risk of damaging the circumﬂex artery increased along with more
distal ablation because the relationship between the circumﬂex
artery and the CS might be even closer at a more distal, “anterior”
position, while myocardial thickness increases at a more poster-
omedial mitral isthmus position [11].
Other potential barriers to successful mitral isthmus ablation are
lack of stability of the ablation catheter and poor tissue contact.
Matsuo et al. demonstrated that the use of Steerable sheaths
signiﬁcantly improved the efﬁcacy of ablation at the mitral isthmus
by improving navigation and stability [16].
Recent studies have suggested that mitral isthmus ablation may
be proarrhythmic if bidirectional block across the line is not
achieved or in the case of conduction recovery [7,17]. Tzeis et al.
reported on the safety and feasibility of an alternative line: the
modiﬁed anterior line, extending from the anterior/anterolateral
mitral annulus to the oriﬁce of the left superior PV, just medial to
the LAA [18]. However, with this technique, a high incidence of
inadvertent isolation of the left atrial appendage (LAA) and delayed
activation of the LAA were potential drawbacks.
The line from the right inferior pulmonary vein to the mitral
annulus can be substituted with the lateral mitral isthmus line for
ablation. However, it was found to have a less favorable anatomy, i.
e., a longer isthmus and greater percentage of ridges [13].
In our patients, ablation at the LA anteroseptal mitral line proved
to be straightforward. Although this line was usually anatomically
longer than the traditional lateral mitral isthmus line, the atrial wall
was relatively thin, it was far from the LAA, and ablation in the CS
was not required, which is desirable in view of the complications
associated with CS ablation.
All our patients had re-isolation of any recovered PV prior to
mapping and ablation of their PMF. We believe that re-isolating the
veins is a cornerstone of successful, long-term treatment of atrial
ﬂutters. This idea was conﬁrmed by the PROPOSE study, in which
targeting the possible triggers of atrial ﬂutter appeared to result in
higher freedom from arrhythmia than did targeting the ﬂutter only [19].
5. Study limitations
This study has several limitations. First, we retrospectively
studied a small cohort of patients in whom ablation was per-
formed at the anteroseptal line instead of that at the usual mitral
isthmus line, based on the operator's preference. Therefore, a
randomized control trial comparing the 2 lines of ablation would
be of great beneﬁt. Second, details about the procedures were
lacking. Unless such data are collected prospectively, it is difﬁcult
to retrieve information about procedure time and ﬂuoroscopy time
when ablation at this line is done in conjunction with PV isolation.
Third, we did not conﬁrm earliest LA activation time during the
intrinsic rhythm, which is done to avoid any unintentional abla-
tion to the Bachmann's bundle region.
6. Conclusion
Ablation at the LA anteroseptal line is a safe and efﬁcacious
treatment for PMF. Unlike ablation at the traditional mitral isthmus
line, ablation at the LA anteroseptal line does not require ablation in
the coronary sinus. A randomized trial will be required to further
compare results after ablation at the LA anteroseptal line with those
after ablation at the traditional mitral isthmus line.
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